Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Menactra Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults

NCT00715910
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Nimenrix, Blood sampling
Biological · Procedure
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 30 Years
Enrollment
818 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

NCT00258856
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Polysaccharide Diphtheria Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Years to 15 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
11
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Marietta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

NCT02199691
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years to 17 Years
Enrollment
1,715 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

NCT00248833
View directory record Official record
Conditions
Meningitis, Meningococcal, Serogroup B
Interventions
25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine, 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2018 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

NCT02140762
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY, Placebo, MenACWY
Biological · Other
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 18 Years
Enrollment
305 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Melbourne, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose Comparison Study of Menactra® in US Children

NCT00700635
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Neisseria Meningitidis
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 10 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 25, 2026, 8:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Safety Surveillance of MenACWY-CRM Vaccine in Children

NCT01452438
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Years to 10 Years
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults

NCT04886154
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo, MenB vaccine, MenACWY vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 50 Years
Enrollment
1,440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
12
States / cities
Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age

NCT01659996
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae Serotype b (Hib)
Interventions
Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 18 Months
Enrollment
1,394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Pinson, Alabama • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

NCT00454909
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine 134612, Menactra®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
10 Years to 25 Years
Enrollment
873 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
10
States / cities
Daly City, California • Fairfield, California • Redwood City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 25, 2026, 8:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study to Learn About the Safety of PENBRAYA During Pregnancy

NCT07768163
View directory record Official record
Conditions
Meningococcal Disease
Interventions
PENBRAYA
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Months to 9 Months
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Making Effective Human Papillomavirus (HPV) Vaccine Recommendations

NCT02377843
View directory record Official record
Conditions
Human Papillomavirus
Interventions
Participatory, Efficient
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

NCT01732627
View directory record Official record
Conditions
Meningitis, Meningococcal Meningitis, Meningococcal Infections, Invasive Meningococcal Disease
Interventions
Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
56 Years and older
Enrollment
301 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Scottsdale, Arizona • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
14
States / cities
Antioch, California • Daly City, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

NCT00450437
View directory record Official record
Conditions
Meningococcal Infections, Meningococcal Meningitis
Interventions
MenACWY CRM, Meningococcal ACWY Conjugate vaccine
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
11 Years to 55 Years
Enrollment
3,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
40
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Fremont, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

NCT02986854
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 55 Years
Enrollment
704 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 25, 2026, 8:00 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
View directory record Official record
Conditions
Meningococcal Vaccine
Interventions
MenABCWY, Saline, rLP2086, MenACWY-CRM
Biological
Lead sponsor
Pfizer
Industry
Eligibility
10 Years to 25 Years
Enrollment
1,610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Fountain Hills, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Sep 25, 2026, 8:00 AM EDT